T his year in the US, 28,660 men are expected to die of prostate cancer, a mortality figure among men surpassed only by lung cancer yet dwarfed by the 186,320 expected new diagnoses. 1 Most men who are diagnosed with prostate cancer ultimately will die of other causes, and the natural history of the disease is relatively protracted even in cases that eventually are lethal. Given this frequently indolent tumor behavior and the potential toxicity of all available treatments, 2 clinicians and researchers alike increasingly recognize the importance of risk stratification of prostate cancer patients and, by extension, the adoption of risk-adapted treatment strategies. Even younger patients with lower risk disease are now eligible for trials of active surveillance at a growing number of institutions, those with low-to intermediate-risk disease may be treated with local monotherapy, those with intermediate-to high-risk disease in many cases should receive multimodal therapy, and those at highest risk ideally should be offered enrollment in clinical trials given the high rates of recurrence with current standard therapies. 3 Although this basic framework is supported by a broad consensus of prostate cancer experts, the question of exactly how patients should be risk stratified, both in clinical practice and for research trials, has become increasingly complex. In 2001, Ross et al published a literature review identifying 42 risk prediction tools for prostate cancer; since then, the field has expanded greatly. 4 In this issue of Cancer, Shariat et al summarize 111 nomograms and other risk prediction instruments, covering multiple decision points in prostate cancer care: prediction of positive biopsy with or without a prior negative biopsy, prediction before surgery of pathologic outcomes, prediction before and after surgery of biochemical endpoints, prediction before radiotherapy of biochemical and clinical endpoints, and prediction of metastases and survival among patients with recurrent disease after primary treatment. 5 It should be noted that the term 'nomogram' denotes a graphic representation of a predictive formula and not the formula itself. Nomograms in oncology generally are derived from Cox proportional hazards regression analyses-including, in many instances in the case of prostate cancer, a cubic spline or other transformation of the prostate-specific antigen level-the results of which can be represented in a variety of ways. Nomograms are one popular option; alternatives include lookup tables 6 and categorized point systems. 7 Readily available statistical software has made the generation of a nomogram based on a Cox model relatively trivial. The result is a profusion of nomograms-there were 11 new prostate cancer nomograms introduced at the 2008 meeting of the American Urological Association alone-which can be confusing to clinicians, researchers, and patients alike. Which should be used in clinical practice or in research: the 'latest and greatest' or the 'tried and true?' Which are the sharpest tools, and which are best suited to improve treatment decision making?
Evaluating Risk Instruments
Shariat et al discuss some of the key features of predictive tools relevant to their implementation, including accuracy, calibration, generalizability, and parsimony-although they do not evaluate most of the instruments subsequently reviewed by these criteria. 5 Aspects of the criteria merit further discussion. Shariat et al consider validation in the context of accuracy and calibration; it is also a critical aspect of generalizability. Many risk instruments are developed based on patients who are treated at 1 or a few, usually high-volume, academic institutions by a relatively small number of clinicians under uniform protocols. Many distinct nomograms are based, in fact, on updated assessment of a few large, previously analyzed cohorts.
An instrument's performance in different settings among other patient groups cannot be assumed to be equivalent, which is why newly developed risk instruments must be subjected to validation studies. Such studies ideally should be performed with cohorts of patients external to the center that developed the instrument; and, in the best case, the analysis should be performed by researchers who are entirely independent of the original center. Few instruments in fact have been evaluated to this level of scrutiny; examples include the Partin tables, 8 the original preoperative and postoperative Kattan nomograms, 9, 10 and the University of California, San Francisco Cancer of the Prostate Risk Assessment (CAPRA) score, 11, 12 which have been validated externally and independently in both American and European cohorts.
Risk prediction tools tend to perform at higher levels of accuracy among academic cohorts compared with community-based cohorts, most likely because of the uniformity of practice in the academic setting as noted above. Thus, for example, the original Kattan preoperative nomogram performs with a c-index between 0.74 and 0.79 in academic cohorts [12] [13] [14] but performs somewhat lower at 0.68 in a community-based cohort. 15 Conversely, the CAPRA score, which yielded a c-index of 0.66 in the original community-based development studies, 7 performed with a c-index as high as 0.81 in academic centerbased validation studies. 11, 12 A final point with respect to validation is that, because distribution and interpretation of prostate cancer risk factors, particularly Gleason grading, have changed significantly over time with artifactual changes in pathologists' grading practices, 16 it is important to periodically verify the relevance of a given instrument to contemporary patients.
Parsimony, which is also called the level of complexity in the review by Shariat et al, 5 warrants additional comment under the more general rubric of applicability. Unlike accuracy and validation, parsimony and applicability are qualitative rather than quantitative criteria and can be considered separately for clinical practice and research. A clinically applicable instrument should be understood readily by clinicians and patients and calculated rapidly during a patient encounter. An instrument that is applicable for risk stratification in clinical research, in turn, must be easy to calculate for hundreds or thousands of patients and must be able to stratify patients into a manageable number of risk strata.
Risk instruments have come to incorporate increasing numbers of variables over time, such that the published nomograms require up to eight steps to use, which can be somewhat cumbersome in practice. For this reason, and given the growing number of instruments applicable to practice, webbased calculators for selected instruments have been made available as noted in the review by Shariat et al. 5 These computer-based tools are easier to use than the paper-based tables and nomograms, but they still require navigation of several screens for each patient. The web calculators also are somewhat of a black box, because the derivations of the nomogram scores are not obvious to users or patients. Indeed, our group developed the CAPRA score specifically in an effort to balance the accuracy of an instrument based on a Cox model with the applicability of a scoring system based on simple addition and requiring neither published tables nor software. 7 Another potential problem with the software approach is that the calculators run multiple nomograms simultaneously, which creates a temptation to give an individual patient comparative likelihoods of outcomes both after surgery and after radiation-the same temptation faces a patient who accesses the website directly. The nomograms cannot be used fairly this way; each was derived with a different cohort of patients, using different definitions of recurrence. Kattan et al, in fact, explicitly stated in their original preoperative nomogram article that the tool was meant to be used only among men who already had elected to undergo radical prostatectomy 14 not among those considering treatment alternatives. The instructions for the original nomogram also specified that the calculated likelihood of recurrence should be presented to the patient with 610% error 14 ; inclusion of the confidence intervals indeed is important but generally is omitted both from more recently published nomograms and from the web-based calculators. Finally, for research purposes, the web calculators would be nearly as difficult to calculate as the published nomograms for large numbers of patients.
Prediction of Distal Endpoints and Across Treatments
Most nomograms and other instruments designed to predict cancer outcomes after treatment have been evaluated for their ability to predict biochemical outcomes after prostatectomy or radiotherapy. However, consistently defining biochemical recurrence is notoriously challenging-by 1 recent count, 152 different definitions were used in studies published between 1991 and 2004, including 53 definitions in prostatectomy series and 99 definitions in radiation series. 17 Moreover, biochemical recurrence does not consistently predict more distal clinical endpoints, such as metastasis, cancer-specific mortality (CSM), and all-cause mortality (ACM). 6 These clinical endpoints may be defined more consistently and are more relevant to patients than biochemical outcomes. However, few pretreatment instruments reported to date have been evaluated at these endpoints. Exceptions include the 3-level classification reported by D'Amico et al, which predicts CSM after surgery or radiation 18 ; a nomogram by Kattan et al that predicts metastasis after externalbeam radiotherapy 19 ; the CAPRA score, which was recently demonstrated to predict metastasis, CSM, and ACM after surgery, radiotherapy, and androgendeprivation therapy 20 ; and novel nomograms introduced by Stephenson et al to predict CSM at 15 years after prostatectomy 21 and Duan et al to predict ACM at 10 years after prostatectomy or radiotherapy. 22 An ideal instrument would be able to risk stratify patients regardless of primary treatment choice; a patient with more aggressive disease features faces increased risk of recurrence regardless of treatment choice, and an instrument should convey a measure of relative risk independent of treatment modality. Pooling or comparing patients who undergo prostatectomy with patients who receive radiotherapy is difficult in studies with biochemical endpoints because of the difficulties in combining definitions of biochemical failure applied to patients who receive different primary treatments. Furthermore, as noted earlier, most published nomograms are intended to be used among patients who already have made a treatment selection. Notable exceptions, mentioned above, include the D'Amico et al classification (tested for prostatectomy and radiation patients), 18 the CAPRA score (prostatectomy, radiation, and androgen deprivation patients), 20 and the nomogram described by Duan et al (prostatectomy and radiation patients). 22 
Conclusions and Future Directions
The only risk assessment instrument endorsed by the American Urological Association's 2007 practice guideline for prostate cancer is the 3-level classification described by D'Amico et al. 3 This classification system has been used extensively in practice and research and certainly excels in terms of parsimony and ease of use. More recent multivariate instruments offer improved accuracy and discrimination, as reviewed by Shariat et al, 5 yet most are significantly more difficult to use, and the plethora of novel instruments runs the risk of producing more confusion than illumination. An open question, in fact, is to what extent, if any, these various tools are being adopted widely in routine contemporary practice.
Changes could be made in the reporting of novel nomograms that may result in easier interpretation and implementation. Confidence intervals should be included with the tools, as in the original Kattan preoperative nomogram.
14 It would be useful to report the predictive formula derived from the Cox model along with the nomogram itself, allowing investigators interested in testing, validating, or adopting the nomogram to incorporate it into statistical programs with relative ease. This change would facilitate the head-to-head comparisons among instruments that Shariat et al appropriately characterize as the best means of objectively ascertaining which have the best performance characteristics. 5 Indeed, a case can be made that, at this point, so many nomograms have been put forward that any new model should be compared explicitly with existing instruments intended for the same clinical scenario (eg, before prostatectomy) in order that the incremental value of the new tool can be assessed objectively. To date, a few articles reporting new nomograms have done this, whereas the majority have not.
Finally, the question of risk stratification in the research setting should be addressed more formally. Shariat et al rightly advise that risk prediction tools should be used more widely in clinical trial design. 5 The score derived from most nomograms, however, is a likelihood of reaching the endpoint in question, expressed on a 100-point scale. This output is well suited for counseling an individual patient but results in an impractical number of strata for research purposes. Thus, if a nomogram is to be used to identify a cohort of high-risk patients for a given protocol, for example, then limits need to be chosen to determine which scores correspond to high risk. Absent clear a priori establishment and validation of these thresholds, different thresholds may be used for each study, or worse, could be chosen post hoc to define subgroups that suit the investigators' purposes. Grouping of scores has been validated for the CAPRA score 11, 12 but not for most nomograms, which may be a barrier to their broader use in the research setting.
Clearly, no risk instrument should be used in isolation to direct patients toward or away from treatment alternatives. Factors not measured by current models, such as baseline quality of life, comorbidity, and life expectancy, all are considered qualitatively in decision making. At least as important are patient treatment preferences, both for immediate versus deferred treatment and for a given form of treatment over another. In fact, the clarity with which patients can understand a risk prediction tool's inputs and results, and thus the extent to which the tool facilitates their decision making, is another important-and generally overlooked-consideration in tool selection.
With numerous prostate cancer biomarkers working their way from bench to bedside, it appears reasonable to hope that the next few years will see novel markers sufficiently validated to be integrated into risk prediction tools. In the interim, clinicians and researchers are faced with the question of which clinically based instruments to use and in what settings. Near the end of their review, Shariat et al call for the development of more nomograms. Equally important will be applying consistent criteria for evaluating both existing and novel nomograms and to determine which in fact are the best tools for the job. Good accuracy and calibration are critical-the tools need to be sharp. What is less clear is what increment in accuracy, as measured by the c-index or other metric, is clinically meaningful. Assuming comparable accuracy among alternatives, the best tools for clinical practice and research should be those that are reliable and easy to handle-that is, those that have been validated most extensively, are easiest to calculate, and make both effective and efficient use of the available clinical data.
